1. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (eds). WHO classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon: International Agency for Research on Cancer; 2015.
2. Warth A, Muley T, Kossakowski C, Stenzinger A, Schirmacher P, Dienemann H, et al. Prognostic impact and clinicopathological correlations of the cribriform pattern in pulmonary adenocarcinoma. J Thorac Oncol. 2015;10:638–44.
3. Tsuta K, Ishii G, Yoh K, Nitadori J, Hasebe T, Nishiwaki Y, et al. Primary lung carcinoma with signet-ring cell carcinoma components: clinicopathological analysis of 39 cases. Am J Surg Pathol. 2004;28:868–74.
4. Minami Y, Iijima T, Onizuka M, Sakakibara Y, Noguchi M. Pulmonary adenocarcinoma with massive lymphocyte infiltration: report of three cases. Lung Cancer. 2003;42:63–8.
5. Kadota K, Yeh YC, Villena-Vargas J, Cherkassky L, Dril EN, Sima CS, et al. Tumor budding correlates with the protumor immune microenvironment and is an independent prognostic factor for recurrence of stage I lung adenocarcinoma. Chest. 2015;148:711–21.
6. Odze RD, Montgomery EA, Wang HH, Lauwers GY, Greenson JK, Carneiro F, et al. Tumor of the esophagus and stomach. In: AFIP atlas of tumor pathology, 4th series, fascicle 28. Arlington, VA: American Registry of Pathology; 2019.
7. Fukayama M, Rugge M, Washington M. Tumours of the stomach. In: WHO classification of tumours of the digestive system. 5th ed. Lyon: International Agency for Research on Cancer; 2019. p. 60–110.
8. Mariette C, Carneiro F, Grabsch HI, van der Post RS, Allum W, de Manzoni G, et al. Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer. 2019;22:1–9.
9. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002;40:127–32.
10. Kawachi H, Eishi Y, Ueno H, Nemoto T, Fujimori T, Iwashita A, et al. A three-tier classification system based on the depth of submucosal invasion and budding/sprouting can improve the treatment strategy for T1 colorectal cancer: a retrospective multicenter study. Mod Pathol. 2015;28:872–9.
11. Pai RK, Cheng YW, Jakubowski MA, Shadrach BL, Plesec TP, Pai RK. Colorectal carcinomas with submucosal invasion (pT1): analysis of histopathological and molecular factors predicting lymph node metastasis. Mod Pathol. 2017;30:113–22.
12. Berg KB, Schaeffer DF. Tumor budding as a standardized parameter in gastrointestinal carcinomas: more than just the colon. Mod Pathol. 2018;31:862–72.
13. Yamaguchi Y, Ishii G, Kojima M, Yoh K, Otsuka H, Otaki Y, et al. Histopathologic features of the tumor budding in adenocarcinoma of the lung: tumor budding as an index to predict the potential aggressiveness. J Thorac Oncol. 2010;5:1361–8.
14. Travis WD, Brambilla E, Muller-Hermelink H, Harris CC (eds). Pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon: International Agency for Research on Cancer; 2004.
15. Sumiyoshi S, Yoshizawa A, Sonobe M, Kobayashi M, Sato M, Fujimoto M, et al. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis. Lung Cancer. 2014;84:281–8.
16. Brierley JD, Gospodarowicz MK, Wittekind C (eds). TNM classification of malignant tumours. 8th ed. Oxford: John Wiley & Sons; 2017.
17. Sonobe M, Kobayashi M, Ishikawa M, Kikuchi R, Nakayama E, Takahashi T, et al. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas. Ann Surg Oncol. 2012;19(Suppl 3):S347–54.
18. Sonobe M, Manabe T, Wada H, Tanaka F. Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain. J Mol Diagn. 2006;8:351–6.
19. Kobayashi M, Sonobe M, Takahashi T, Yoshizawa A, Ishikawa M, Kikuchi R, et al. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer. Anticancer Res. 2011;31:4619–23.
20. Nakajima N, Yoshizawa A, Kondo K, Rokutan-Kurata M, Hirata M, Furuhata A, et al. Evaluating the effectiveness of RNA in-situ hybridization for detecting lung adenocarcinoma with anaplastic lymphoma kinase rearrangement. Histopathology. 2017;71:143–9.
21. Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;17:889–97.
22. Rokutan-Kurata M, Yoshizawa A, Sumiyoshi S, Sonobe M, Menju T, Momose M, et al. Lung adenocarcinoma with MUC4 expression is associated with smoking status, HER2 protein expression, and poor prognosis: clinicopathologic analysis of 338 cases. Clin Lung Cancer. 2017;18:e273–81.
23. Moreira AL, Joubert P, Downey RJ, Rekhtman N. Cribriform and fused glands are patterns of high-grade pulmonary adenocarcinoma. Hum Pathol. 2014;45:213–20.
24. Kuang M, Shen X, Yuan C, Hu H, Zhang Y, Pan Y, et al. Clinical significance of complex glandular patterns in lung adenocarcinoma: clinicopathologic and molecular study in a large series of cases. Am J Clin Pathol. 2018;150:65–73.
25. Emoto K, Eguchi T, Tan KS, Takahashi Y, Aly RG, Rekhtman N, et al. Expansion of the concept of micropapillary adenocarcinoma to include a newly recognized filigree pattern as well as the classical pattern based on 1468 Stage I lung adenocarcinomas. J Thorac Oncol. 2019;14:1948–61.
26. Ohe M, Yokose T, Sakuma Y, Miyagi Y, Okamoto N, Osanai S, et al. Stromal micropapillary component as a novel unfavorable prognostic factor of lung adenocarcinoma. Diagn Pathol. 2012;7:3.
27. Sica G, Yoshizawa A, Sima CS, Azzoli CG, Downey RJ, Rusch VW, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010;34:1155–62.
28. Yoshida A, Tsuta K, Watanabe S, Sekine I, Fukayama M, Tsuda H, et al. Frequent ALK rearrangement and TTF-1/p63 coexpression in lung adenocarcinoma with signet-ring cell component. Lung Cancer. 2011;72:309–15.
29. Kim H, Jang SJ, Chung DH, Yoo SB, Sun P, Jin Y, et al. A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelialmesenchymal transition markers than other genotype. PLoS ONE. 2013;8:e76999.
30. Voena C, Varesio LM, Zhang L, Menotti M, Poggio T, Panizza E, et al. Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1. Oncotarget. 2016;7:33316–30.
31. Taira T, Ishii G, Nagai K, Yoh K, Takahashi Y, Matsumura Y, et al. Characterization of the immunophenotype of the tumor budding and its prognostic implications in squamous cell carcinoma of the lung. Lung Cancer. 2012;76:423–30.
論文の公開元へ
